Picks and Pans - The Buy-Side View for 2012
Monday, February 13th, 12:00pm-12:55pm
Portfolio managers and senior buy-side analysts forecast the year ahead in biotech. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by the Biotechnology Industry Organization’s (BIO) Industry Analysis Team. Panelists will field a range of questions from valuations and volatility to challenges and opportunities facing institutional investors today.
Stephen Sands, Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard
Alexander J. Denner, PhD, (former) Managing Director, Icahn Associates
Rajiv Kaul, Portfolio Manager, Fidelity Select Biotechnology Portfolio, Fidelity
Greg Martinez, Portfolio Manager, Diamondback Capital Management LLC
Deepa R. Pakianathan, PhD, General Partner, Delphi Ventures
Alexander J. Denner, PhD
(former) Managing Director, Icahn Associates
Dr. Alexander J. Denner, Ph.D was a Managing Director at Carl C. Icahn. He was also a Managing Director at various Carl C. Icahn affiliated entities, including Icahn Partners LP and Icahn Partners Master Fund LP since 2006. Dr. Denner served as a Senior Managing Director at Icahn Enterprises, L.P., which he joined in 2006. He served as the Chief Executive Officer at ImClone Systems Corporation until August 27, 2007. Dr. Denner has a strong background in biotechnology and biotechnology investments. He served as a Portfolio Manager, healthcare investments at Viking Global Investors L.P. from April 2005 to May 2006. Dr. Denner served as a Portfolio Manager of Healthcare and Biotechnology Mutual Funds at Morgan Stanley Investment Management for the Health Sciences Trust Fund and the Biotechnology Fund. He joined Morgan Stanley in 1996. Dr. Denner served in a variety of positions at Morgan Stanley Investment Management and its predecessor companies including healthcare group head, healthcare sector leader, and biotechnology research analyst. He has also worked at the MITRE Corporation and the Charles Stark Draper Laboratory. Dr. Denner has been a Non Executive Chairman of Enzon Pharmaceuticals Inc. at sigma-tau s.p.a since July 2009. He has been a Director of Enzon since May 2009. Dr. Denner has been a Director of ImClone Systems Corporation since May 2006, Amylin Pharmaceuticals Inc. since June 2009 and Biogen Idec Inc. since June 2009. He serves as a Director of HyperMed, Inc. Dr. Denner served as a Director of Adventrx Pharmaceuticals Inc. from October 26, 2006 to October 16, 2009. He performed research in Biomedical Engineering at Yale University where he was awarded a Ph.D. degree. Dr. Denner received an M.S. and M.Phil. degrees from Yale University, and B.S. degree from Massachusetts Institute of Technology.
Portfolio Manager, Fidelity Select Biotechnology Portfolio, Fidelity
Rajiv Kaul is a portfolio manager and research analyst for Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing and other financial products and services to more than 20 million individuals, institutions and financial intermediaries.
Mr. Kaul manages Fidelity Select Biotechnology Portfolio and Fidelity Advisor Biotechnology Fund. Mr Kaul has spent 15 years at Fidelity. During this period, Mr Kaul has been widely recognized for his leadership within the biotech industry and has often been ranked among the top rated healthcare investors in the US.
He is a graduate of Harvard University and worked at Mckinsey & Company prior to joining Fidelity.
Portfolio Manager, Diamondback Capital Management LLC
Greg Martinez is a Portfolio Manager for Diamondback Capital focusing on the healthcare sector. Prior to joining Diamondback, Mr. Martinez was a Senior Vice President at Pequot Capital, which he joined in 2004. At Pequot Greg worked on various healthcare subsectors, including biotechnology, pharmaceuticals, medical devices and services. Mr. Martinez began his career with DCF Capital in 1998, where he focused on biotechnology stocks across the market capitalizations. Mr. Martinez earned his B.A. in History from Duke University and his M.B.A. in Accounting and Finance from Northwestern University’s Kellogg School of Management.
Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard
Stephen Sands is a Managing Director and Global Co-Head of Lazard’s Healthcare Group. He has worked on behalf of both domestic and international life science clients in the biotech, specialty pharma and pharmaceutical sectors. Mr. Sands is also on the Board of Directors of Lazard Capital Markets.
Mr. Sands advised some of the largest pharmaceutical and biotechnology transactions ever done including Pfizer’s acquisition of Pharmacia and Warner Lambert, UCB’s acquisition of Schwarz Pharma and Celltech, Hoechst on the formation of Aventis and the acquisition by Glaxo of Wellcome. He has also provided financial advise to leading biotech/specialty pharma companies such as Abraxis, Alpharma, APP Pharmaceuticals, Biogen, Hypnion, Imclone, OSI, MGI, Protez, Rosetta, and ViroPharma. In addition, Mr. Sands has assisted numerous companies to raise capital in the public markets including Amicus, Dendreon, Enzo Biochem, Poniard, Targanta, Synta, Viropharma and Xenoport.
Prior to joining Lazard in 1994, Mr. Sands was a Partner in the health care practice of McKinsey & Company. While on sabbatical from McKinsey, Mr. Sands co-founded two biotechnology companies -- Enzytech and Opta Foods -- where he served as Vice President, Business Development and Treasurer. Prior to their sale Mr. Sands was a Director of National Imaging Associates, Inc (Magellan), and Isogen LLC (Monsanto). Mr. Sands has been the featured Keynote Speaker and participated as a panelist at numerous biotechnology conferences. He is a member of the Brookings/Gates Global Heath Innovative Financing Advisory Group. Mr. Sands was also the New York Biotechnology Association’s (NYBA) inaugural recipient of The Cures Start Here® Business Leader of the Year Award 2008.
Mr. Sands received a B.A. in Biology from Oberlin College, a B.S. and M.S. in Chemical Engineering from Washington University in St. Louis, and an M.B.A. in Finance from New York University.